PDN have received 1.3m (EUR) in funding from investor Onassis Foundation. The funding will see the continued development of PDN's wearable medical technology for continuous monitoring and treating of movement disorders which is anticipated to assist in the treatment of chronic diseases like Parkinson's disease.
MBM’s Alexander Lamley, Senior Associate from the corporate team, advised PDN on the UK legal aspects of receiving the funding.
Nikolaos Moschos, President of the board of directors at PDN, commented: 'This funding will ensure the continued development of our innovative wearable medical technology that will significantly benefit sufferers of debilitating movement disorders and illnesses such as Parkinson's disease. Alex Lamley has worked tirelessly with us to complete this deal on tight timeframes and the team at MBM has provided fantastic support, legal and commercial advice that has made the difference for PDN on securing this new investor.'
Alexander Lamley added: ‘PD Neurotechnology has continued to advance its much needed technology in this field and this latest investment is a great reflection of the value the founding team, led by Nikos Moschos, has built.’
MBM Commercial advises on all aspects of corporate law with particular expertise in both acting for a range of investor companies and companies receiving investment. For further information please get in touch with Alexander Lamley, email@example.com.